Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000155811 | SCV000205522 | uncertain significance | not specified | 2014-03-19 | criteria provided, single submitter | clinical testing | The Leu1002Val variant in RBM20 has not been previously reported in individuals with cardiomyopathy, but has been identified in 1/1384 African American chromoso mes by the NHLBI Exome Sequencing Project (http://evs.gs.washington.edu/EVS/). C omputational prediction tools favor a benign role. The affected amino acid is no t well conserved in evolution and 1 mammal (megabat) carries a valine (Val) at t his position, raising the possibility that this change may be tolerated. Additio nal information is needed to fully assess the clinical significance of the varia nt. |
Labcorp Genetics |
RCV000647173 | SCV000768961 | likely benign | Dilated cardiomyopathy 1DD | 2024-12-17 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001567804 | SCV001791555 | likely benign | not provided | 2021-01-11 | criteria provided, single submitter | clinical testing | This variant is associated with the following publications: (PMID: 25351510) |
Ambry Genetics | RCV002433685 | SCV002748848 | uncertain significance | Cardiovascular phenotype | 2024-07-03 | criteria provided, single submitter | clinical testing | The p.L1002V variant (also known as c.3004C>G), located in coding exon 11 of the RBM20 gene, results from a C to G substitution at nucleotide position 3004. The leucine at codon 1002 is replaced by valine, an amino acid with highly similar properties. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. |